The Non-Cystic Fibrosis Bronchiectasis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of non-cystic fibrosis bronchiectasis has seen substantial growth in recent years. The market was valued at $3.5 billion in 2024 and is projected to increase to $3.74 billion in 2025 with a compound annual growth rate (CAGR) of 6.9%.
The non-cystic fibrosis bronchiectasis market is forecasted to reach a size of $4.82 billion in 2029, with a compound annual growth rate (CAGR) of 6.6%.
Download Your Free Sample of the 2025 Non-Cystic Fibrosis Bronchiectasis Market Report and Uncover Key Trends Now!The drivers in the non-cystic fibrosis bronchiectasis market are:
• Rising incidence and prevalence of the condition
• Advances in diagnostic technologies
• Growing geriatric population
• Increased diagnosis awareness and government support for treatment efforts
The non-cystic fibrosis bronchiectasis market covered in this report is segmented –
1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types
2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments
3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses
The trends in the non-cystic fibrosis bronchiectasis market are:
• The market is being shaped by advances in personalized medicine and the emergence of new biomarkers.
• There is a trend towards digital health solutions and the integration of AI and machine learning into treatments.
• The shift towards home-based care is another significant trend.
• Increasing patient-centric approaches and the growth of mobile health (mHealth) solutions contribute to market changes.
The major players in the non-cystic fibrosis bronchiectasis market are:
• Pfizer Inc.
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2023